0
0
1/19/23 at 3:50pm
Organization
Targetedonc.com
Author
Russ Conroy
33 words
0
Comments
New findings from the phase 2 INFINITY trial shows promise for tremelimumab and durvalumab in patients with gastric/GEJ adenocarinoma.
You are the first to view
https://www.targetedonc.com/view/tremelimumab-plus-durvalumab-showed-promising-activity-safety-in-gastric-gej-adenocarcinoma
Create an account
or login to join the discussion